Biotech veteran Jack Reich thought he had retired in 2002 after selling his cardiovascular gene therapy firm Collateral Therapeutics Inc. to Schering AG in a $140 million stock-for-stock deal, but further developments in the field brought him back to the executive fold, heading up 2008 start-up Renova Therapeutics Inc.